FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
More News: Canagliflozin | Dapagliflozin | Diabetes | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Invokana | Podcasts | Urology & Nephrology | Warnings